The Treatment Strategies for Intermediate‐Advanced Hepatocellular Carcinoma Based on Albumin–Bilirubin Grade: A Multicenter Retrospective Cohort Study
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72415 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 05.11.2026. Verfasst von Kang Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bilirubin, Serum Albumin. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Three-Year Action Plan for Clinical Skills and Innovation Capacity Enhancement of Tertiary Hospitals in Shanghai, Meng Chao Talent Leadership Reserve Training Program, Shanghai Science and Technology Commission Explorer Program.
Abstract (Originalsprache)
Background
To evaluate whether the albumin–bilirubin (ALBI) grade modifies the association of combined locoregional plus systemic therapy versus systemic therapy alone with outcomes in unresectable hepatocellular carcinoma (HCC).
Methods
This multicente retrospective study enrolled 525 patients, stratified by the established ALBI grade cut‐off into ALBI‐low (Grade 1, ALBI score ≤ −2.60, n = 257) and ALBI‐high (Grade 2/3, n = 268). Propensity score matching (PSM) was performed in the whole cohort and within each ALBI stratum; survival, tumor response, and safety were compared in matched cohorts, with effect modification tested by a treatment × ALBI interaction term.
Results
After PSM, combination therapy was associated with better overall survival (OS) (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.34–0.76; p = 0.001) and progression‐free survival (PFS) (HR 0.73, 95% CI 0.56–0.96; p = 0.024). The association was observed in ALBI‐low patients (OS: HR 0.32, 95% CI 0.18–0.56, p < 0.001; PFS: HR 0.59, 95% CI 0.41–0.85, p = 0.004), who also had higher objective response rates by modified Response Evaluation Criteria in Solid Tumors (mRECIST; 70.9% vs. 38.8%, p < 0.001) and RECIST 1.1 (55.3% vs. 30.1%, p < 0.001). No significant association was seen in ALBI‐high patients (OS: HR 0.83, 95% CI 0.47–1.45, p = 0.504; PFS: HR 1.06, 95% CI 0.71–1.58, p = 0.792), and the treatment × ALBI interaction was significant for OS ( p = 0.019) and PFS ( p = 0.035). Overall and Grade 3–4 adverse reactions were comparable, but elevated bilirubin (33.0% vs. 17.0%, p = 0.012) and transaminases (35.1% vs. 20.2%, p = 0.022) were more frequent with combination therapy in the ALBI‐high cohort.
Conclusion
In this multicenter real‐world cohort, combination therapy was associated with better outcomes in patients of ALBI Grade 1 but not Grade 2/3, in whom hepatic toxicity was more frequent, and the exploratory treatment × ALBI interaction was significant. ALBI grade may help identify patients more likely to benefit from combined locoregional and systemic therapy, although prospective validation is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
- Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
- Shanghai Baoshan District Songnan Town Community Health Center, Shanghai, China.
- Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
- Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Kang Liang, Xiaorong Pan, Yuxuan Lin, Kongying Lin, Jing Li, Huichuan Sun, Kui Wang
Förderung
- Three-Year Action Plan for Clinical Skills and Innovation Capacity Enhancement of Tertiary Hospitals in Shanghai
- Meng Chao Talent Leadership Reserve Training Program
- Shanghai Science and Technology Commission Explorer Program
- Shanghai Municipal Health Commission Research Project
- Jiading District Health Commission 2025 Research Project
- Third Affiliated Hospital of the Naval Medical University 2025 Department Project-Clinical Research Training Program
- Tengfei Engineering Talent Cultivation Program of Third Affiliated Hospital of Naval Medical University
Zitieren
APA
Liang, K., Liu, J., Pan, X., Lin, Y., Lin, K., Xue, H., Li, J., Sun, H., Wang, K., & China Liver Cancer Study Group Young Investigators (CLEAP) (2026). The Treatment Strategies for Intermediate‐Advanced Hepatocellular Carcinoma Based on Albumin–Bilirubin Grade: A Multicenter Retrospective Cohort Study. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72415
Vancouver
Liang K, Liu J, Pan X, Lin Y, Lin K, Xue H, et al. The Treatment Strategies for Intermediate‐Advanced Hepatocellular Carcinoma Based on Albumin–Bilirubin Grade: A Multicenter Retrospective Cohort Study. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72415
BibTeX
@article{Liang2026,
author = {Liang, Kang and Liu, Jianwei and Pan, Xiaorong and Lin, Yuxuan and Lin, Kongying and Xue, Hui and Li, Jing and Sun, Huichuan and Wang, Kui and China Liver Cancer Study Group Young Investigators (CLEAP), China Liver Cancer Study Group Young Investigators (CLEAP)},
title = {The Treatment Strategies for Intermediate‐Advanced Hepatocellular Carcinoma Based on Albumin–Bilirubin Grade: A Multicenter Retrospective Cohort Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72415}
}
EUVIMED